Document Detail


The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients--a European perspective.
MedLine Citation:
PMID:  16115174     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Glaucoma is a condition affecting one or both eyes with raised intraocular pressure (IOP). IOP should be reduced to prevent progression of visual field loss. This study investigates the cost-effectiveness of bimatoprost compared with latanoprost as first-line monotherapies in the treatment of glaucoma in Austria, Finland and France. On the basis of a single multicentre, randomised, investigator-masked controlled trial, a 6- and 12-month cost-effectiveness model was designed following the treatment recommendations from the European Glaucoma Society. Treatment changes due to insufficient IOP reduction and adverse events were included. The cost-effectiveness analysis showed that the need for adjunctive therapy was the major cost driver. On the basis of evidence from the randomised, investigator-masked clinical trial (RCT), the cost-effectiveness analysis found that bimatoprost was a cheaper and a more effective treatment strategy compared with latanoprost. This was true for all three countries and all IOP targets between 13 and 20 mmHg. The cost-effectiveness result may be generalised to a European setting and perspective.
Authors:
E Tuil; A B Hommer; P B Poulsen; T L Christensen; P Buchholz; J Walt; S Holmstrom
Related Documents :
11127574 - Healon5 versus viscoat during cataract surgery: intraocular pressure, laser flare and c...
911734 - Trabeculectomy: long-term follow-up.
16952094 - First day review after uncomplicated phacoemulsification: is it necessary?
16276274 - Transconjunctival suture adjustment for initial intraocular pressure control after trab...
19793174 - Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia afte...
17753794 - Submergence of the new jersey coast.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of clinical practice     Volume:  59     ISSN:  1368-5031     ISO Abbreviation:  Int. J. Clin. Pract.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-08-23     Completed Date:  2006-02-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9712381     Medline TA:  Int J Clin Pract     Country:  England    
Other Details:
Languages:  eng     Pagination:  1011-6     Citation Subset:  IM    
Affiliation:
CHNO des Quinze Vingts, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amides
Antihypertensive Agents / adverse effects,  economics*,  therapeutic use
Austria
Chemotherapy, Adjuvant / economics
Cloprostenol / analogs & derivatives
Cost-Benefit Analysis
Drug Costs
Finland
France
Glaucoma / drug therapy*
Humans
Lipids / adverse effects,  economics*,  therapeutic use
Models, Economic*
Ophthalmic Solutions
Prostaglandins F, Synthetic / adverse effects,  economics,  therapeutic use
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Amides; 0/Antihypertensive Agents; 0/Lipids; 0/Ophthalmic Solutions; 0/Prostaglandins F, Synthetic; 0/bimatoprost; 130209-82-4/latanoprost; 40665-92-7/Cloprostenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Open tension-free Cooper ligament repair for femoral hernia.
Next Document:  Unscheduled healthcare resource use among asthma patients receiving low-dose inhaled corticosteroids...